Cannabis manufacturer Select mixed up THC and CBD products, Oregon says, and that’s why unsuspecting consumers got high

State regulators say the Oregon manufacturer Select, also known as Cura Cannabis, evidently mixed up two lines of products at its Portland manufacturing site. A CBD product, at left, was not supposed to contain THC, but bottles sold contained high levels of the psychoactive ingredient associated with marijuana. A THC product, at right, was sold without sufficient doses of THC. Both have been recalled.Oregon Liquor and Cannabis Commission

Read the full article here: https://www.oregonlive.com/business/2021/09/cannabis-manufacturer-select-mixed-up-thc-and-cbd-products-oregon-says-and-thats-why-unsuspecting-consumers-got-high.html

For more information and for relevant resources, visit the IASIC Library here. The IASIC medical library contains peer-reviewed medical literature about marijuana/ cannabis that is translated into terminology that allows for informed decision-making by the general public.

Like this article?

Share on Facebook
Share on Twitter
Share on Linkdin
Share on Pinterest

Related Posts

Libby Stuyt Interview on Randy Tobler show

Exciting News! Libby Stuyt’s Interview on Randy Tobler Show! Hey everyone, we wanted to share some thrilling news! The brilliant Dr. Libby Stuyt recently had an enlightening interview on Randy Tobler Show. Dr. Stuyt is known for her groundbreaking work in the field of addiction medicine and mental health. Her insights are nothing short of

Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies

Introduction Cannabis contains over 100 cannabinoids, of which Δ9-tetrahydrocannabinol and cannabidiol are the most clinically relevant. Tetrahydrocannabinol is a partial agonist at CB1 and binds CB2 receptors. CB1 is widely expressed by central and peripheral neurones but also by immune cells and other type of cells in the brain and in the periphery, and when

Medical marijuana access and prolonged opioid use among adolescents and young adults

Abstract Background and Objectives Laws liberalizing access to medical marijuana are associated with reduced opioid analgesic use among adults, but little is known about the impact of such policies on adolescents and young adults. Methods This retrospective cohort study used 2005 to 2014 claims from MarketScan® Commercial database, which covers all 50 states and Washington

Scroll to Top